🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Lendormin tablet

    Boehringer Ingelheim

    Healthy

    phase 1 small molecule completed

    1 trial

  2. Lenvatinib

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma Stage IIIa

    phase 1 small molecule active

    1 trial

  3. Linperlisib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Large Granular T Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  4. Loncastuximab Tesirine and Durvalumab

    ADC Therapeutics SA

    Diffuse Large B-Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  5. Lubiprostone

    Takeda

    Chronic Constipation, Methanogenesis

    phase 1 small molecule completed

    1 trial

  6. Lumason® contrast agent

    United Therapeutics Europe Ltd

    Mitochondrial Myopathies

    phase 1 small molecule active

    1 trial

  7. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Extensive Stage Lung Small Cell Carcinoma

    phase 1 small molecule active

    1 trial

  8. Lysogenic HSV virus.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HNSCC

    phase 1 mab active

    1 trial

  9. M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors

    The George Institute

    Patients with pretreated, metastatic or locally advanced cancer for the dose escalation part and dose expansion cohorts in patients with advanced triple-negative breast cancers and advanced cancers with ATM mutation.

    phase 1 other active

    1 trial

  10. MIRROR; Multispectral and bimodal fluorescent guided surgery (FGS) of high-grade glioma for refining margin assessment: A phase 1 dose finding study using Cetuximab-IRDye800CW- combined with 5-ALA

    Disc Medicine

    Glioblastoma

    phase 1 other active

    1 trial

  11. MK-4318 CIDF Target Engagement Study

    Merck Sharp and Dohme

    Pain

    phase 1 other active

    1 trial

  12. MLN1117

    Takeda

    Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

    phase 1 small molecule terminated

    1 trial

  13. MLN4924

    Takeda

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  14. MSC-derived exosomes

    Regeneron Ireland Designated Activity Company (DAC)

    Long COVID-19 Syndrome

    phase 1 mab active

    1 trial

  15. MSC2156119J

    Merck KGaA, Darmstadt, Germany

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  16. Magellan®

    United Therapeutics Europe Ltd

    Acute Burns

    phase 1 other active

    1 trial

  17. ManNAc

    Ultragenyx UK Limited

    Hereditary Inclusion Body Myopathy (HIBM)

    phase 1 small molecule completed

    1 trial

  18. Master Protocol of Sotorasib (AMG 510) in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)

    Amgen

    Advanced Solid Tumors Kirsten Rat Sarcoma (KRAS) pG12C Mutation

    phase 1 other active

    1 trial

  19. Metronidazole gel 1

    BRIGHT MINDS BIOSCIENCES INC.

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  20. Mevrometostat Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

    Pfizer Australia Pty Ltd

    Castration Resistant Prostate Cancer (CRPC), Follicular Lymphoma (FL), Small Cell Lung Cancer (SCLC), Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 1 other active

    1 trial

  21. Microgestin®

    IRONWOOD PHARMACEUTICALS INC

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  22. Modified Gegen Qinlian Decoction

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ulcerative Colitis

    phase 1 small molecule active

    1 trial

  23. Multiple-Dose Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions.

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  24. Multiple-Dose Study in Healthy Participants Under Fasting Conditions to Evaluate the Bioequivalence of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide SR 1.5 mg and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg.

    The George Institute

    No medical condition.

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources